A CDC report shows comorbid conditions exist in 73.1% of all arthritis patients. Based on NHIS survey data, the number of patients with 2 or more comorbid conditions has increased from 21.8% in 2001 to 25.5% in 2012. Most affected were older adults (≥65 years), women, wh
NHANES data shows eczema is associated with a higher rate of fractures and osteoporosis. Of the nearly 5,000 people included in the study, seven percent reported a diagnosis of eczema.
Dr. Angus Worthing writes of patient angst over rising copays. Expensive specialty medications are the frequent target of "sharing" the rising costs of medications and making them the patients responsibility and not the insurers.
Dalbeth and coworkers studied 92 patients with gout and using DECT scanning have shown those with urate deposition on DECT were 8.5-fold more likely to have erosive disease on plain radiographs.
Researchers from the University of Manchester investigated self-reported adherence to biologic treatment in RA and found that 41% of patients were non-adherent to adalimumab therapy at least once, and 23% were nonadherent overall. http://bit.ly/1KA2
Although the cause is not clear, women who have weight loss surgery have a higher risk of thinning bones (osteoporosis) and fractures over time, according to a new analysis of a Swedish study.
25% of Medicare beneficiaries with rheumatoid arthritis use high-cost biologics. Yazdany and coworkers have analyzed a national cohort of beneficiaries and compared Medicare part D plans.
52.5 million US adults (22.7%) have arthritis with half of these claiming activity limitation because of arthritis and pain. Many arthritis patients have comorbid conditions including heart disease (49%), diabetes (47%) and obesity (31%).
IL-17 inhibitors are being developed for treatment of psoriasis, psoriatic arthritis and axial spondyloarthritis. Broadalumab has been in phase II & III trials and been developed by a partnership between Amgen and Astra-Zeneca.
A prospective study of sildenafil was conducted in 25 centers that included 83 patients and 192 digital ulcers at entry. The odds of healing ulcers was less, but not significant, for sildenafil.
Three phase III studies of sarilumab (SARIL-RA-TARGET, -EASY and -ASCERTAIN), a fully-human IL6 receptor antibody, have been reported and met primary end points in these pivotal clinical trials.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
